O.P. ALEKSEEVA

Nizhny Novgorod Regional Clinical Hospital named after N.A. Semashko, 190 Rodionova St., Nizhny Novgorod, Russian Federation, 603126

Alekseeva O.P. —D. Med. Sc., Professor, Director of the Regional Gastroenterology Center, tel. (831)438-93-52, e-mail: al_op@mail.ru

The article presents a comparative assessment of the irritable bowel syndrome treatment, symptomatic therapy-resistant, in the complex therapy of 29 patients during the 8 weeks with the use of the tricyclic antidepressant amitriptyline and melatonin receptor-agonistic antidepressant agomelatine. Statistically significant decreasing of depressive disorders and improving the quality of life is stated according to the depression scales indicators (CES-D, HADS and scale of life quality assessment IBS-QOL) in both groups of patients. In the agomelatine treatment group, treatment efficacy and tolerability were significantly more pronounced.

Key words: irritable bowel syndrome, depression, antidepressants, quality of life.

REFERENCES

1. Drossman D.A. The functional gastrointestinal disorders and Rome III process. Gastroenterology. 2006. April, vol. 130, pp. 1377-1390. (in Russ.)

2. Thompson W.G. The Road to Rome. Gastroenterology. 2006, vol. 130, pp. 1552-1551.

3. Wang W., Pan G., Qian J. Cognitive therapy for patient with refractory irritable bowel syndrome. Zhonghua Nei Ke Za Zhi, 2002, vol. 41, pp. 156-159. (in Russ.)

4. Sans de la Garza C.L., Gammez Guerrero S., Serrano Guerra E., Gutierrez Casares J.R. Recurrent abdominal pain in primary care: study of functional recurrent abdominal pain. An. Esp. Pediatr, 2000, November, vol. 53, no. 5, pp. 458-468.

5. Drossman D.A., Toner B.B., Whitehead W.E. et al. Cognitive-behavioural therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders. Gastroenterology, 2003, vol. 125, pp. 19-31.

6. Halpert A., Dalton C.B. Diamant N.E. at al. Clinical response to tricyclic antidepressants in functional bowel disorders is not related to dosage. Am. J. Gastroenterol, 2005, vol. 100, pp. 664-671.

7. Andryushchenko A.V., Drobizhev M.D., Dobrovol’skiy A.V. Comparative evaluationscalesCES-DandHADSdepressionin the diagnosis ofgeneral medicalpractice. Zhurnal nevrologii i psikhiatrii im. Korsakova[Journalof Neurology andPsychiatry named Korsakov], 2003, no. 5, pp. 11-18.

8. Zigmond A.S., Snaith R.P. The Hospital Anxiety and Depression scale. Acta Pychiatr. Scand, 1983,   vol. 67, pp. 361-370.

9. Drossman D.A., Patrick D.L., Whitehead W.E. et al. Further validisation of the IBS-QOL: disease-specific quality of life questionnaire. Am. J. Gastroenterol, 2000, vol. 95, pp. 999-1007.

10. Gubler E.V. Vychislitel’nye metody analiza i raspoznavaniya patologicheskikh protsessov[Computational methods ofanalysis and recognition ofpathological processes]. L.: Meditsina, Leningr. otd-nie, 1978, 294 p.

11. Ivashkin V.T. Sindrom razdrazhennoy kishki. Rossiyskiy zhurnal gastroenterologii i gepatologii [Russian Journal ofGastroenterology and Hepatology]. 1993, no. 2 (3), pp. 27-31. (in Russ.)

12. Longstreth G.F., Thompson W.G., Chey W.D. et al. Funktsional’nye rasstroystva kishechnika. Klinicheskaya gastroenterologiya i gepatologiya. Russkoe izdanie [ClinicalGastroenterology and Hepatology. Russianedition], 2008, no. 4, pp. 224-235. (in Russ.)

13. Ford A.C., Talley N.J., Schoenfeld P.S. at al. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut, 2009, March, vol. 58 (3), pp. 367-378.

14. Emsley R. Efficacy and safety of agomelatine (25mg/50mg), a melatonergic and specific serotonergic antidepressant, in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled study. Int. J. Neuropsychopharm, 2004, vol. 7 (S1), abstract, pp. 102-174.

15. Montgomery S.A., Kasper S. Severe depression and antidepressants. Focus on pooled analysis of placebo-controlled studies on agomelatine. Int. Clin. Psychopharmacol, 2007, vol. 22, pp. 283-291.

16. Kennedy S. Sexual function in remitted depressed patient following agomelatine and venlafaxine XR treatment. Eur. Neuropsychopharm. 2005, vol. 15 (S3), abstract, p. 2111.